CADM1 ELISA kit
- Known as:
- CADM1 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-CADM1-Hu
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- CADM1 ELISA kit
Related genes to: CADM1 ELISA kit
- Gene:
- CADM1 NIH gene
- Name:
- cell adhesion molecule 1
- Previous symbol:
- TSLC1, IGSF4
- Synonyms:
- NECL2, ST17, BL2, SYNCAM, IGSF4A, Necl-2, SYNCAM1, RA175
- Chromosome:
- 11q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-11-02
- Date modifiied:
- 2016-10-05
Related products to: CADM1 ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: CADM1 ELISA kit
- The molecular basis for species-specific thermal adaptation in vertebrate sensory systems is not well understood. We show that a single-amino-acid change in the pore domain of ion channel transient receptor potential ankyrin 1 (TRPA1) during the synapsid-diapsid split rewired its heat sensitivity. Many oviparous vertebrates retaining the ancestral residue display TRPA1 heat activation, protecting embryonic development under high temperatures, whereas selection for an aspartate in mammals reduced thermal responsiveness. Blocking heat-activated TRPA1 in oviparous embryos impaired dorsal-root-ganglion axon growth, disrupted myelination, and caused limb weakness at hatching. Mechanistically, TRPA1-mediated Ca influx triggers nuclear translocation of SP1, activating and . Together, these results uncover an unexpected developmental role of TRPA1 in heat resilience, linking a single mutational event to embryonic survival under thermal stress and highlighting ion-channel evolution in adaptation. - Source: PubMed
Publication date: 2026/09/02
Feng Tian-YuDong WenqiZheng DongHan LeiChen JiatongWu XuanyeLu XiancuiYang ShilongDu Wei-Guo - Osteosarcoma (OS) is the most common human primary bone cancer, primarily affecting children and young adults. While the survival rate of patients diagnosed with localized OS is ∼65%, this decreases to ∼20% for patients with metastatic disease, and recurrent disease remains largely incurable. Therefore, identifying new therapeutic strategies is urgently needed for metastatic and refractory OS. This study analyzes the surfaceomes and global proteomes of 22 unique OS patient-derived xenografts (PDXs) using mass spectrometry to identify surface proteins for potential immunotherapeutic targeting. Both methods identify known OS-associated surface candidates including LRRC15, MMP14, MRC2, and CADM1, and several poorly characterized targets, including ROR2 and TMEM119. Both ROR2 and TMEM119 display robust expression in OS tissues but only limited or no expression in normal pediatric tissues, and loss of both targets reduces the migration of OS cells. These data provide a resource of surface proteins as potential immunotherapeutic targets in OS. - Source: PubMed
Publication date: 2026/08/26
Mooney BrianChu XiaojieNegri Gian LucaLizardo Michael MSong HarleyMarsh AlisonDelaidelli AlbertoHuang Yue ZRouleau MelanieSpencer Sandra EShraim RawanHamilton Amber KMagesh SruthiZhang WendongBudhathoki YogeshCannon Matthew VRoberts RyanGorlick RichardSweet-Cordero AlejandroDiskin Sharon JMaris John MLi WeiMorin Gregg BSorensen Poul H - Adult T-cell leukemia/lymphoma (ATL) is a rare T-cell malignancy, where the chronic type often progresses to an acute form in the presence of poor prognostic factors. We report a remarkable case of chronic-type ATL that achieved long-term hematologic and molecular remission following methimazole treatment for concomitant Graves' disease. A 58-year-old woman was diagnosed with chronic-type ATL in 2022. Her disease showed gradual progression with elevated soluble interleukin-2 receptor (sIL-2R) levels and lactate dehydrogenase. In 2023, she developed Sjögren's syndrome and Graves' disease. Following the initiation of methimazole for hyperthyroidism, her abnormal lymphocyte counts and sIL-2R levels unexpectedly and rapidly decreased. She has maintained clinical stability for over two years without any cytotoxic chemotherapy. Multi-color flow cytometry confirmed the disappearance of the CD4+/CADM1+/CD7- ATL cell population in the peripheral blood. Furthermore, longitudinal genomic profiling using Target-seq revealed a significant reduction in the variant allele frequencies of major driver clones, including a PDCD1 frameshift mutation, and a shift from monoclonal expansion to a polyclonal HTLV-1 carrier state. This case provides the first clinical evidence of a potential anti-ATL effect of methimazole and underscores the importance of the endocrine-immune axis in HTLV-1-associated malignancies, warranting further investigation into antithyroid therapy as a novel treatment strategy for indolent ATL. - Source: PubMed
Publication date: 2026/07/30
Fuji ShigeoSuzuki KakoWatanabe EriTsuchiya KazumiYamagishi Makoto - The Hippo pathway has been implicated in the tumorigenesis of hepatocellular carcinoma (HCC). We aimed to determine the expression of Hippo pathway-related proteins in HCC using immunohistochemical staining and compare the data among patients with different underlying clinical background diseases. We collected 40 resected HCC formalin-fixed paraffin-embedded samples and categorized them into 4 groups according to pre-existing conditions [17 samples of alcohol consumption (HCC-A) and 6, 8, and 9 samples with hepatitis B virus infection (HCC-B), hepatitis C virus infection (HCC-C), and metabolic diseases (HCC-M), respectively]. Using immunohistochemistry, we investigated the Hippo pathway-related proteins YAP1, CADM1, and SOX9. Hypertension was the most common disease (72.5%) among patients with HCC, followed by diabetes mellitus (47.5%). Regarding the background liver disease, significant findings of steatohepatitis (SH) were observed in the HCC-A (35.3%) and HCC-M (88.9%) groups compared with those in the HCC-B (16.7%) and HCC-C (0%) groups. A significant finding of metabolic dysfunction-associated SH (MASH) was also observed in the HCC-M group (88.9%), and liver cirrhosis was predominantly observed in the HCC-C group (100%). Twenty-seven patients had Hippo-inactive status, and 13 patients had active status. SH was more predominant in the HCC-M group with Hippo inactivity (100%) than in the HCC-A group (50.0%). The average tumor size was significantly larger in the Hippo-inactive group than in the Hippo-active group. Hippo pathway-associated proteins could serve as potential therapeutic targets for MASH and MASH-related HCC if the Hippo pathway is inactivated. - Source: PubMed
Publication date: 2026/07/22
Nishida HarutoMatsuura KeikoDaa Tsutomu - Depressive disorders are a leading cause of global disability, yet gene expression studies in Middle Eastern populations remain scarce. This study investigated peripheral blood expression of seven candidate genes, previously identified in animal models and early-onset depression, in adults with and without depressive disorders in United Arab Emirates (UAE). - Source: PubMed
Publication date: 2026/07/01
Nawaz RukhsanaAl Awadhi EmanAl Mughairbi FadwaBashir AsmaAndrade GabrielBokhari Syed AliJavaid Syed FahadHamid Abdalla A R M